腹膜透析相关腹膜炎治愈率的影响因素:PDOPPS研究
该研究为前瞻性观察性队列,纳入7国1631例腹膜炎发作,发现总体治愈率65%;革兰阴性、多菌和真菌腹膜炎治愈率低,自动化腹膜透析、艾考糊精使用、经验性氨基糖苷及环丙沙星治疗革兰阴性腹膜炎与较高治愈率相关。
要点
- 总体腹膜炎治愈率为65%。
- 革兰阴性、多菌和真菌腹膜炎治愈率显著低于革兰阳性。
- 自动化腹膜透析、艾考糊精使用、经验性氨基糖苷及环丙沙星治疗革兰阴性腹膜炎与较高治愈率相关。
核心结论
- 腹膜炎治愈率因患者特征、腹膜炎特征和可修改的治疗实践而异。
- 不同感染病原体和抗生素方案的治愈率差异提示需进一步研究病原体特异性治疗。
研究设计与样本
- 前瞻性观察性队列研究,纳入澳大利亚、新西兰、加拿大、日本、泰国、英国和美国的1631例腹膜炎发作(1190例患者,126个中心)。
主要发现
- 总体65%的腹膜炎发作获得治愈。
- 与革兰阳性腹膜炎相比,革兰阴性(AOR 0.41 [95% CI 0.30-0.57])、多菌(AOR 0.30 [95% CI 0.20-0.47])和真菌(AOR 0.01 [95% CI 0.00-0.07])腹膜炎治愈的比值比更低。
- 自动化腹膜透析相比持续不卧床腹膜透析治愈比值比更高(AOR 1.36 [95% CI 1.02-1.82])。
- 中心艾考糊精使用每增加10%治愈比值比更高(AOR 1.06 [95% CI 1.01-1.12])。
- 经验性氨基糖苷使用(AOR 3.95 [95% CI 1.23-12.68])和革兰阴性腹膜炎使用环丙沙星相比头孢他啶(AOR 5.73 [95% CI 1.07-30.61])与更高治愈比值比相关。
关键数值与推荐
- 治愈定义为腹膜炎发作后50天内无死亡、转血液透析、腹膜透析导管拔除、复发或再发性腹膜炎。
临床怎么用
- 对于革兰阴性腹膜炎,可考虑使用环丙沙星而非头孢他啶。
- 经验性使用氨基糖苷可能提高治愈几率。
- 自动化腹膜透析和艾考糊精使用与更高治愈率相关。
局限性
- 样本选择可能存在偏倚,普遍性可能有限。
- 残余混杂和适应证混杂限制推断。
- 中心层面治疗变量可能无法捕捉患者层面治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Peritoneal dialysis (PD)-associated peritonitis is a significant PD-related complication. We describe the likelihood of cure after a peritonitis episode, exploring its association with various patient, peritonitis, and treatment characteristics. STUDY DESIGN: Observational prospective cohort study. SETTING & PARTICIPANTS: 1,631 peritonitis episodes (1,190 patients, 126 facilities) in Australia, New Zealand, Canada, Japan, Thailand, the United Kingdom, and the United States. EXPOSURE: Patient characteristics (demographics, patient history, laboratory values), peritonitis characteristics (organism category, concomitant exit-site infection), dialysis center characteristics (use of icodextrin and low glucose degradation product solutions, policies regarding antibiotic self-administration), and peritonitis treatment characteristics (antibiotic used). OUTCOME: Cure, defined as absence of death, transfer to hemodialysis (HD), PD catheter removal, relapse, or recurrent peritonitis within 50 days of a peritonitis episode. ANALYTICAL APPROACH: Mixed-effects logistic models. RESULTS: Overall, 65% of episodes resulted in a cure. Adjusted odds ratios (AOR) for cure were similar across countries (range, 54%-68%), by age, sex, dialysis vintage, and diabetes status. Compared with Gram-positive peritonitis, the odds of cure were lower for Gram-negative (AOR, 0.41 [95% CI, 0.30-0.57]), polymicrobial (AOR, 0.30 [95% CI, 0.20-0.47]), and fungal (AOR, 0.01 [95% CI, 0.00-0.07]) peritonitis. Odds of cure were higher with automated PD versus continuous ambulatory PD (AOR, 1.36 [95% CI, 1.02-1.82]), facility icodextrin use (AOR per 10% greater icodextrin use, 1.06 [95% CI, 1.01-1.12]), empirical aminoglycoside use (AOR, 3.95 [95% CI, 1.23-12.68]), and ciprofloxacin use versus ceftazidime use for Gram-negative peritonitis (AOR, 5.73 [95% CI, 1.07-30.61]). Prior peritonitis episodes (AOR, 0.85 [95% CI, 0.74-0.99]) and concomitant exit-site infection (AOR, 0.41 [95% CI, 0.26-0.64]) were associated with a lower odds of cure. LIMITATIONS: Sample selection may be biased and generalizability may be limited. Residual confounding and confounding by indication limit inferences. Use of facility-level treatment variables may not capture patient-level treatments. CONCLUSIONS: Outcomes after peritonitis vary by patient characteristics, peritonitis characteristics, and modifiable peritonitis treatment practices. Differences in the odds of cure across infecting organisms and antibiotic regimens suggest that organism-specific treatment considerations warrant further investigation.
引用
- Al Sahlawi M, Zhao J, McCullough K, et al. Variation in Peritoneal Dialysis-Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis. 2021. PMID: 34052357. doi:10.1053/j.ajkd.2021.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。